References

Global, Regional, and National Burden of Diabetes From 1990 to 2021, With Projections of Prevalence to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021

10.1016/s0140-6736(23)01301-6 · 2023 · External reference

Gaps of Medication Treatment Management Between Guidelines and Real‐World for Inpatients With Type 2 Diabetes in China From Pharmacist's Perspective

10.3389/fendo.2022.900114 · 2022 · External reference

Comparative Effectiveness of Glucose‐Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis

10.7326/m20-0864 · 2020 · External reference

Guidelines on Primary Healthcare for Type 2 Diabetes in China, 2025

10.1136/fmch-2025-003765 · 2025 · External reference

Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)

10.1002/agm2.12294 · 2024 · External reference

PCR71 Assessing Adherence to SGLT2 Inhibitor Add‐On to Metformin Therapy in Chinese T2DM Patients: A Real‐World Retrospective Cohort Study

10.1016/j.jval.2024.03.1950 · 2024 · External reference

A Class Comparison of Medication Persistence in People With Type 2 Diabetes: A Retrospective Observational Study

10.1007/s13300-017-0361-5 · 2018 · External reference

Prevalence and Risk Factors of MAFLD and Its Metabolic Comorbidities in Community‐Based Adults in China: A Cross‐Sectional Study

10.1016/j.dsx.2024.102973 · 2024 · External reference

Estimating Global Prevalence of Metabolic Dysfunction‐Associated Fatty Liver Disease in Overweight or Obese Adults

10.1016/j.cgh.2021.02.030 · 2022 · External reference

Management of Metabolic‐Associated Fatty Liver Disease: The Diabetology Perspective

10.3748/wjg.v29.i1.126 · 2023 · External reference

Sodium‐Glucose Cotransporter‐2 Inhibitors in Combination With Other Glucose‐Lowering Agents for the Treatment of Type 2 Diabetes Mellitus

10.4103/ijem.ijem_162_17 · 2018 · External reference

DPP‐4 Inhibitor Plus SGLT‐2 Inhibitor as Combination Therapy for Type 2 Diabetes: From Rationale to Clinical Aspects

10.1080/17425255.2016.1215427 · 2016 · External reference

Fixed‐Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview

10.1007/s12325-016-0434-2 · 2017 · External reference

Safety, Efficacy, and Bioavailability of Fixed‐Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review

10.1016/j.curtheres.2017.01.005 · 2017 · External reference

Metformin: Update on Mechanisms of Action and Repurposing Potential

10.1038/s41574-023-00833-4 · 2023 · External reference

Structural Basis of Inhibition of the Human SGLT2‐MAP17 Glucose Transporter

10.1038/s41586-021-04212-9 · 2022 · External reference

Empagliflozin: A Review in Type 2 Diabetes

10.1007/s40265-018-0937-z · 2018 · External reference

Cardio‐Renal Protection With Empagliflozin

10.21037/atm.2016.10.36 · 2016 · External reference

Empagliflozin in Patients With Chronic Kidney Disease

10.1056/nejmoa2204233 · 2023 · External reference

Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes

10.2337/dc16-0522 · 2016 · External reference

The Safety of Empagliflozin Plus Metformin for the Treatment of Type 2 Diabetes

10.1080/14740338.2018.1497159 · 2018 · External reference

Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study

2023 · External reference

Cost‐Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First‐Line Therapy in Patients With Type 2 Diabetes Mellitus

10.1016/j.eprac.2021.07.018 · 2022 · External reference

Guideline for the Prevention and Treatment of Type 2 Diabetes Mellitus in China (2024 Edition)

2025 · External reference

Achievement of Target A1C <7.0% (<53 Mmol/Mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice

10.2337/ds17-0082 · 2019 · External reference

Types and Rates of Major Adverse Cardiovascular Events in Antithrombotic Trials: A Systematic Review and Meta‐Analysis

10.1016/j.cjca.2025.08.358 · 2025 · External reference

Kidney Outcomes Using a Sustained ≥40% Decline in eGFR: A Meta‐Analysis of SGLT2 Inhibitor Trials

10.1002/clc.23665 · 2021 · External reference

Spotlight on Empagliflozin/Metformin Fixed‐Dose Combination for the Treatment of Type 2 Diabetes: A Systematic Review

10.2147/ppa.s85748 · 2016 · External reference

Empagliflozin/Metformin Fixed‐Dose Combination: A Review in Patients With Type 2 Diabetes

10.1080/14656566.2016.1258062 · 2016 · External reference

Empagliflozin as Add‐On to Metformin in Patients With Type 2 Diabetes: A 24‐Week, Randomized, Double‐Blind, Placebo‐Controlled Trial

10.2337/dc13-2105 · 2014 · External reference

Empagliflozin Treatment Effects Across Categories of Baseline HbA1c, Body Weight and Blood Pressure as an Add‐On to Metformin in Patients With Type 2 Diabetes

10.1111/dom.14234 · 2021 · External reference

The Effect of Low and High Dose Empagliflozin on HbA1c and Lipid Profile in Type 2 Diabetes Mellitus: A Real‐World Data

2020 · External reference

The Association Between Sarcopenia and Diabetes: From Pathophysiology Mechanism to Therapeutic Strategy

10.2147/dmso.s410834 · 2023 · External reference

Association Between Sarcopenia and Poor Glycemic Control in Older Adults With Type 2 Diabetes Mellitus

10.3390/diseases11040175 · 2023 · External reference

Pathogenesis and Comprehensive Treatment Strategies of Sarcopenia in Elderly Patients With Type 2 Diabetes Mellitus

10.3389/fendo.2023.1263650 · 2024 · External reference

Glucometabolic Efficacy of the Empagliflozin/Metformin Combination in People With Type 1 Diabetes and Increased Cardiovascular Risk: A Sub‐Analysis of a Pilot Randomized Controlled Trial

10.3390/jcm13226860 · 2024 · External reference

Long‐Term Treatment With Metformin in Obese, Insulin‐Resistant Adolescents: Results of a Randomized Double‐Blinded Placebo‐Controlled Trial

10.1038/nutd.2016.37 · 2016 · External reference

Baseline HbA1c Predicts Attainment of 7.0% HbA1c Target With Structured Titration of Insulin Glargine in Type 2 Diabetes: A Patient‐Level Analysis of 12 Studies

10.1111/dom.12096 · 2013 · External reference

Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial

10.2337/dc23-1782 · 2024 · External reference